---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044830"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:02:35.650349+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics reports Q3 net income of $1.4M but raises going concern doubt as cash stands at $3.2M

## Summary
- Net income $1.4M ($0.16 basic EPS) vs $1.8M a year ago; revenue $14k from NIH grants.
- Operating expenses surged to $5.3M from $1.5M, driven by R&D and G&A increases.
- Cash, cash equivalents, and restricted cash $3.2M; company expects insufficient funds for 12 months.
- Expects ~$10M from Juvenescence warrant exercise via side letter, but still substantial doubt about going concern.
- Lead candidate SER-252 (apomorphine) for Parkinson's planned for clinical testing in 2025; partnership with Enable Injections.

## SEC filing metadata
- accession: 0001493152-24-044830
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315224044830/0001493152-24-044830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315224044830/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044830
- JSON: https://secwatch.observer/filing/0001493152-24-044830.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.